id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
work_5sk7tf57hfcrdka5jfmlrjp64y	Timothy R. Donahue	Impact of Splenectomy on Thrombocytopenia, Chemotherapy, and Survival in Patients with Unresectable Pancreatic Cancer	2010.0	8	.pdf	application/pdf	4935	663	52	Impact of Splenectomy on Thrombocytopenia, Chemotherapy, and Survival in Patients Background Patients with unresectable pancreatic cancer (PDAC) or endocrine tumors (PET) often develop splenic vein Methods From 2001 to 2009, 15 patients with recurrent or unresectable PDAC or PET underwent splenectomy for Conclusions Splenectomy for patients with unresectable PDAC or PET who developed hypersplenism and thrombocytopenia that limited the administration of chemotherapy, significantly increased platelet counts, and led to resumption of Patients with PDAC had better disease-specific survival as compared to historical controls. patients with locally advanced unresectable PDAC or PETs From 2001 to 2009, 15 patients with unresectable pancreatic cancer who developed hypersplenism and thrombocytopenia, which limited the administration of their The platelet counts significantly responded to splenectomy in all patients, preoperative (median 87×103/µL, patients with PDAC had a median survival of 20 months Impact of Splenectomy on Thrombocytopenia, Chemotherapy, and Survival in Patients with Unresectable Pancreatic Cancer	./cache/work_5sk7tf57hfcrdka5jfmlrjp64y.pdf	./txt/work_5sk7tf57hfcrdka5jfmlrjp64y.txt